AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $62.38B |
| Gross Profit (TTM) | $51.02B |
| EBITDA | $21.28B |
| Operating Margin | 29.60% |
| Return on Equity | 22.60% |
| Return on Assets | 8.59% |
| Revenue/Share (TTM) | $40.25 |
| Book Value | $33.35 |
| Price-to-Book | 5.60 |
| Price-to-Sales (TTM) | 4.63 |
| EV/Revenue | 5.12 |
| EV/EBITDA | 15.09 |
| Quarterly Earnings Growth (YoY) | 23.50% |
| Quarterly Revenue Growth (YoY) | 6.70% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 76.63% |
Volatility is currently expanding
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism portfolio.
AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with and beyond the disease. Announced at Breast Cancer Canada's Canadian Night reception during the European Society for Medical Oncology (ESMO) Congress in Madrid, the funding will support two Canadian research initiatives, each receiving $100,000 to advance innovative approaches to.
Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Watson and Verizon. Bottom contributors include Cummins, Applied Materials, Brookfield Renewable, Home Depot and AstraZeneca.
Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company's oncology growth strategy.
AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed.
During the quarter, we added 4 new positions and exited 14, bringing the number of positions in the Fund to 33. We initiated a position in Biogen Inc., a company that we believe is in the early stages of a transformation. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor's clinical trial readout.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
